somatostatin 1-28

Somatostatin receptor agonist, derived from the post-translational cleavage of prosomatostatin.

Somatostatin 1-28 acetate circulates in human plasma. Approximately 46% of the total somatostatin-like immunoreactivity in plasma is due to Somatostatin 1-28 acetate.

Somatostatin-28 (1-12) is a somatostatin fragment which is monitored in brain tissue to track processing of somatostatin.

Somatostatin-28 (1-14) is an N-terminal fragment of the neuropeptide somatostatin-28. Somatostatin 28 arises from the posttranslational cleavage of prosomatostatin, which in turn is derived from a large precursor, preprosomatostatin.

[Tyr12] Somatostatin 28 (1-14) is an analogue of the N-terminal fragment [1] of the neuropeptide Somatostatin-28, specifically the first 14 amino acids of the sequence.

[Nle8] Somatostatin (1-28), a derivative of somatostatin (1-28) with norleucine (Nle) substituting for methionine at position 8, enhances amylase release and elevates cyclic AMP levels in pancreatic acini [1].

GLP-1(28-36)amide acetate inhibits mitochondrial permeability transition with antioxidant, anti-diabetic and cardioprotection activities.

GLP-1(28-36)amide, a C-terminal nonapeptide derived from the cleavage of GLP-1 by neutral endopeptidase (NEP), is a significant product. It functions as an antioxidant and primarily targets the mitochondrion, where it effectively inhibits mitochondrial permeability transition (MPT). This compound exhibits anti-diabetic properties and demonstrates cardioprotection effects[1].

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, is one of three mammalian natriuretic peptides (NPs) that exerts endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide holds promise for cardiovascular diseases research.

Tyr-Somatostatin-28 is a somatostatin derivative consisting of Somatostatin-28 with an additional Tyrosine amino acid [1].

Carperitide acetate (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate), a 28-amino acid hormone, is naturally produced and released by the human heart upon cardiac injury or mechanical stretch. This compound effectively inhibits the secretion of endothelin-1 in a dose-dependent manner.

Atrial Natriuretic Peptide (1-28), rat is the major circulating form of ANP in rats.

GLP-1(28-36)amide TFA, a C-terminal nonapeptide derived from GLP-1 cleavage by neutral endopeptidase (NEP), acts as an antioxidant targeting mitochondria. It inhibits mitochondrial permeability transition (MPT), exhibiting anti-diabetic and cardioprotective effects [1].

Atrial natriuretic factor (1-28) from both human and porcine sources is a powerful suppressor of pro-opiomelanocortin (POMC) mRNA, while it only has a modest inhibition effect on βEP-LI release.

Atrial Natriuretic Peptide (ANP) (1-28),rat (TFA) is the main circulating forms of Atrial Natriuretic Peptide (ANP) in rats, which strongly inhibit the secretion of Ang II - stimulated endothelin-1.

β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding.